CytoMed Therapeutics (GDTC) Other Non-Current Assets (2024 - 2025)
CytoMed Therapeutics' (GDTC) quarterly Other Non-Current Assets came in at $28062.0 in Q2 2025, down 94.39% year-over-year from $500000.0 in Q2 2024, and down 7.86% quarter-over-quarter from $30456.0 in Q4 2024.
Powered by 
Analysis
CytoMed Therapeutics (GDTC) Other Non-Current Assets (2024 - 2025) Analysis & Trends
CytoMed Therapeutics has disclosed Other Non-Current Assets across 2 years of filings, most recently posting $28062.0 for Q2 2025.
- In Q2 2025, Other Non-Current Assets fell 94.39% year-over-year to $28062.0; the TTM figure through Jun 2025 stood at $28062.0 (down 94.39% YoY), while the FY2024 annual figure was $30456.0, changed N/A from the prior year.
- Other Non-Current Assets came in at $28062.0 for Q2 2025 at CytoMed Therapeutics, down from $30456.0 in the prior quarter.
- In the past five years, Other Non-Current Assets ranged from a high of $500000.0 in Q2 2024 to a low of $28062.0 in Q2 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Krystal Biotech | 10.21 Bn | 9.37 Bn | 112.79 Mn | 284,000.00 |
| 2 | CRISPR Therapeutics AG | 5.04 Bn | 5.04 Bn | - | 37.71 Mn |
| 3 | Iovance Biotherapeutics | 3.65 Bn | 3.36 Bn | 55.72 Mn | 6.43 Mn |
| 4 | Legend Biotech | 3.54 Bn | 2.57 Bn | 251.50 Mn | 25.50 Mn |
| 5 | uniQure | 2.95 Bn | 2.95 Bn | 5.49 Mn | 4.54 Mn |
| 6 | Beam Therapeutics | 2.55 Bn | 2.55 Bn | - | 7.86 Mn |
| 7 | Precigen | 2.39 Bn | 2.39 Bn | 52.17 Mn | 708,000.00 |
| 8 | Sarepta Therapeutics | 2.16 Bn | 1.37 Bn | 251.87 Mn | 146.15 Mn |
| 9 | Vericel | 1.93 Bn | 1.77 Bn | 56.40 Mn | 233,000.00 |
| 10 | CytoMed Therapeutics | 9.78 Mn | 8.17 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2025 | 28,062.00 |
| Dec 31, 2024 | 30,456.00 |
| Jun 30, 2024 | 500,000.00 |